Sinopharm Accord announced that it expects the net profit attributable to shareholders of the listed company for 2024 to be between 561 million and 760 million yuan, a decrease of 52.48%-64.92% compared to the same period last year. The net profit after deducting non-recurring gains and losses is expected to be between 497 million and 696 million yuan, a decrease of 54.59%-67.58% compared to the same period last year. The basic earnings per share are expected to be between 1.01 yuan/share and 1.37 yuan/share. The decline in performance is mainly due to the impact of changes in industry policies and intensified market competition in the retail sector. It is expected to recognize an impairment provision for goodwill and intangible assets of approximately 876 million to 1.07 billion yuan, which is expected to reduce the net profit attributable to shareholders of the listed company during the reporting period by 505 million to 618 million yuan
